p53Status in Multiple Human Urothelial Cancers: Assessment for Clonality by the Yeast p53 Functional Assay in Combination with p53 Immunohistochemistry
Open Access
- 1 February 2000
- journal article
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 91 (2) , 181-189
Abstract
Multifocal synchronous or metachronous tumor development is a common observation in human urothelial cancer cases. However, the underlying mechanism has remained obscure. We have employed a new tool to investigate the p53 gene status, the yeast p53 functional assay, in combination with immunohistochemistry in a total of 50 tumor samples from 32 cases with urothelial cancers, including 8 with multiple synchronous tumor development and 2 demonstrating metachronous tumors. p53 mutations were found in 13 cases (9 with missense mutations, 3 with deletion, 1 with splicing mutation) by the yeast p53 functional assay. p53 protein overexpression was seen in all 9 cases with missense mutations, but in only one of the 4 cases with nonsense mutations. Two tumors without p53 mutation also showed positive p53 immunoreactivity. Overall, p53 abnormalities including mutations and/or protein overexpression were found in 15 (47%) cases. p53 abnormalities were significantly more frequent in non‐papillary and in high grade tumors. Loss of the wild type allele in addition to a p53 mutation was suggested in 8 of the 15 (53%) cases. All 4 cases with mutations in multiple synchronous tumors had identical p53 mutations in the separate urothelial cancers, strongly suggestive of monoclonality. The one case with multiple metachronous tumors, in contrast, was characterized by variation in the p53 status, indicative of different clonal origins. In conclusion, combined assessment for p53 status as used here (yeast p53 functional assay plus immunohistochemistry) may provide insights into the molecular mechanisms of urothelial carcinogenesis.Keywords
This publication has 30 references indexed in Scilit:
- Clonal analysis of urothelial carcinomas in C3H/HeNBALB/c chimeric mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamineCarcinogenesis, 1998
- Inactivation of p53 results in high rates of homologous recombinationOncogene, 1997
- Heterogeneity of chromosome 17 and erbB‐2 gene copy number in primary and metastatic bladder cancerCytometry, 1995
- Metachronous multifocal development of urothelial cancers by intraluminal seedingThe Lancet, 1993
- Screening patients for heterozygous p53 mutations using a functional assay in yeastNature Genetics, 1993
- p53 mutations in phenacetin-associated human urothelial carcinomasCarcinogenesis, 1993
- Nuclear Overexpression of p53 Protein in Transitional Cell Bladder Carcinoma: A Marker for Disease ProgressionJNCI: Journal of the National Cancer Institute, 1993
- Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 allelesCell, 1992
- c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladderThe Lancet, 1992
- p53 Mutations in Human CancersScience, 1991